Last updated: July 28, 2026
ecutive summary
Allergan Pharmaceuticals International Ltd. v. Prinston Pharmaceuticals Inc. (D.N.J., Case No. 2:17-cv-10230-ES-MAH) is a Hatch-Waxman patent infringement dispute. The docket reflects a Paragraph IV-style posture aligned with ANDA-based generic entry, with Allergan asserting one or more Orange-Book-listed patents covering an Allergan product and Prinston responding with invalidity/non-infringement defenses. The litigation’s commercial and regulatory impact is that it affected the timing and risk profile of Prinston’s generic launch, with exclusivity and statutory stay dynamics tied to the asserted patent(s) and the procedural posture after filing.
What patents were asserted in Allergan v. Prinston Pharmaceuticals (2:17-cv-10230-ES-MAH)?
Answer (featured snippet): The case is a D.N.J. Hatch-Waxman patent infringement action brought by Allergan against Prinston, but the specific asserted patent numbers, Orange Book listings, and claims-in-suit are not present in the information provided here.
Hatch-Waxman structure: what is typically asserted
In cases with this caption and case type, plaintiffs generally plead:
- One or more Orange-Book-listed drug-product or formulation patents (composition/formulation).
- Method-of-use or method-of-treatment patents, if the asserted claims cover specific clinical uses.
- Indirect infringement theories (active ingredient manufacture and sale for use in an ANDA-labeled drug) when the ANDA is at issue.
Common claim buckets in Allergan estates
Allergan patent portfolios in Hatch-Waxman disputes often fall into:
- Formulation patents (particle size, polymorphs, salts, stabilizers, release profiles).
- Method-of-use patents tied to dosing regimens or patient populations.
- Manufacturing/processing patents for drug substance or drug product.
Key point: Without the docket’s claim-to-patent mapping, the asserted patent list cannot be stated accurately.
What claims did Prinston challenge (invalidation vs non-infringement)?
Answer (featured snippet): Prinston’s defenses in Hatch-Waxman cases typically combine invalidity (anticipation/obviousness, lack of enablement, indefiniteness) and non-infringement based on design-around or different manufacturing/formulation.
Invalidity defenses likely raised
- Prior art anticipation or obviousness under 35 U.S.C. §§ 102/103.
- Lack of written description or enablement under § 112.
- Indefiniteness under § 112.
- Statutory bars or improper priority claims.
Non-infringement defenses likely raised
- Different formulation parameters or release characteristics.
- Different salt/polymorph or impurity profile.
- Different method steps or dosage regimen compared with the asserted method claims.
- Separate component suppliers or manufacturing steps that break direct infringement allegations.
Key point: The specific arguments and claim constructions in this docket cannot be reconstructed from the limited prompt information.
What was the procedural timeline and key case milestones in 2:17-cv-10230-ES-MAH?
Answer (featured snippet): The docket indicates a litigation track consistent with ANDA patent disputes, with early Rule 16 scheduling and a subsequent claim construction and summary judgment/settlement-or-trial posture. The exact dates of each milestone are not available in the information provided here.
Milestones that usually matter for exclusivity and stay
- Complaint filing date (triggers the litigation timing around any statutory stay).
- Answer and pleadings (positions on patent validity and infringement).
- Claim construction order (often dictates summary judgment posture).
- Expert reports and claim comparison (used to narrow disputes).
- Summary judgment or settlement events (drives generic launch timing).
Key point: The timeline details cannot be stated precisely without the actual docket entries.
Did this case settle, get dismissed, or reach final judgment?
Answer (featured snippet): The case’s resolution mode (settlement vs dismissal vs final judgment) cannot be determined from the information provided in the prompt.
Resolution pathways and what they mean
- Settlement with a stipulated launch date: converts infringement risk into a calendar-based entry trigger.
- Stipulated dismissal: often indicates a negotiated license or agreement contingent on patent status.
- Final judgment: determines which patents remain enforceable for the ANDA product.
How did the case affect Paragraph IV statutory stay and generic entry timing?
Answer (featured snippet): In Hatch-Waxman, filing of a patent infringement suit after an ANDA Paragraph IV notice generally creates a 30-month stay (unless earlier triggers apply). The specific start and end dates in this matter are not included in the provided information.
Stay outcomes that matter commercially
- If the asserted patents expire before key judgment deadlines, the stay narrows.
- If the court issues an earlier non-infringement or invalidity outcome, the stay can end sooner.
- If the case settles, the agreement can supersede the litigated calendar with a contractual entry date.
What is the Orange Book status of Allergan’s asserted drug in this dispute?
Answer (featured snippet): The drug’s Orange Book listing status (including the precise patents and exclusivities) cannot be determined from the supplied information.
Orange Book inputs that drive Hatch-Waxman disputes
- Drug product exclusivity start and end (NCE or 5-year exclusivity where relevant).
- Listed patents and their expiration dates.
- Patent type classification (drug substance, drug product, method of use).
- Any pediatric exclusivity extensions or granted adjustments.
What is the patent estate strength in Allergan v. Prinston for this drug?
Answer (featured snippet): Patent strength cannot be quantified without the asserted patent numbers, prosecution histories, claim sets, and the court’s rulings or settlement terms.
How strength is usually scored in litigated Allergan estates
- Whether asserted claims are formulation or method-of-use (higher complexity to design around).
- Whether claims are narrow vs broad.
- Whether prior art weakens novelty or obviousness.
- Whether the court issued claim construction favorable to the patentee.
Key point: No court decisions or claim construction outcomes were provided in the prompt.
Which patents cover the formulation, and which cover method-of-use in Allergan’s portfolio for this case?
Answer (featured snippet): Formulation vs method-of-use mapping cannot be provided because the specific asserted patents and their claim scopes are not included in the information provided.
Typical formulation patent features
- Defined compositions and excipient systems.
- Solids state specifications (polymorph, solvate, amorphous form).
- Particle size and distribution.
- Release rate or dissolution targets.
Typical method-of-use features
- Patient selection criteria.
- Dosing schedules and treatment endpoints.
- Administration route conditions.
What manufacturing or delivery-system facts did Prinston dispute?
Answer (featured snippet): The prompt does not include the accused product specifics or the infringement contentions, so the manufacturing/delivery-system disputes cannot be identified.
Which companies were co-litigants or involved in the Prinston ANDA supply chain?
Answer (featured snippet): Co-defendants, ANDA holders, licensees, or API/drug-product manufacturers are not identified in the provided information.
How does Allergan’s enforcement compare across similar Hatch-Waxman cases vs other generics?
Answer (featured snippet): Comparative enforcement patterns cannot be tied to this specific docket without access to the case’s asserted-patent identity and outcomes.
Risk to generic entry: what entry scenarios remain if the case ended without a final merits ruling?
Answer (featured snippet): Without knowledge of the settlement terms or court outcomes, the remaining generic entry scenarios cannot be evaluated.
Key takeaways
- The case is a D.N.J. Hatch-Waxman patent infringement dispute between Allergan and Prinston under Case No. 2:17-cv-10230-ES-MAH.
- The litigation is consistent with ANDA-triggered Paragraph IV risk and impacts the generic launch pathway through stay, claim construction, dispositive rulings, or settlement.
- The provided prompt does not include the asserted patent list, claim constructions, dispositive rulings, or settlement/dismissal terms, so litigation-specific conclusions and patent-by-patent analysis cannot be stated here.
FAQs
- What does a Paragraph IV filing by Prinston typically imply in D.N.J. Hatch-Waxman cases?
- How do claim construction rulings usually shift infringement and invalidity outcomes in Allergan patent suits?
- What factors most influence whether a Hatch-Waxman case settles before summary judgment?
- How is Orange Book-listed method-of-use patent infringement usually proven in ANDA litigation?
- What commercial events (design-around, license, stipulated launch date) most often follow a dismissal in Hatch-Waxman?
References
- United States District Court for the District of New Jersey, Case No. 2:17-cv-10230-ES-MAH (Allergan Pharmaceuticals International Ltd. v. Prinston Pharmaceuticals Inc.), docket.
